Lexicon (LXRX) Pharmaceuticals announced details of its “SOtaglifloziN in Patients with SymptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy, SONATA-HCM,” study were presented on Saturday, May 17. The study design was disclosed in Belgrade, Serbia at one of the premier international heart failure meetings: Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology. Enrollment is underway in SONATA-HCM, with all study sites in 20 countries expected to be operational by September 2025. Lexicon believes there is potential for the study results to support a supplemental new drug application for sotagliflozin for both obstructive and non-obstructive HCM.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXRX:
- Lexicon Pharmaceuticals’ Earnings Call Highlights Strategic Gains
- Lexicon Pharmaceuticals: Hold Rating Amid Strategic Restructuring and Clinical Uncertainties
- Lexicon Pharmaceuticals: Strong Financials and Promising R&D Pipeline Justify Buy Rating
- Lexicon Pharmaceuticals Reports Promising Start to 2025
- Lexicon reports Q1 EPS (7c), consensus (10c)